Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137724 | 0.90 | POLB (0.36) | NR4A2ALOX5POLBLMNAPARP1 | |
| SCHEMBL21986865 | 0.83 | LMNA (0.40) | NR4A2POLBLMNAPARP1SMN1; SMN2 | |
| SCHEMBL1081543 | 0.82 | LMNA (0.39) | NR4A2ALOX5POLBLMNAPARP1 | |
| SCHEMBL1080724 | 0.82 | QPCT (0.44) | POLBLMNAPARP1 | |
| SCHEMBL24754415 | 0.81 | SMN1; SMN2 (0.39) | PARP1SMN1; SMN2ACLYEGLN1 | |
| SCHEMBL6137705 | 0.81 | DPP4 (0.48) | POLBLMNAPARP1ACLYGAA | |
| SCHEMBL1081831 | 0.79 | ALDH1A1 (0.40) | NR4A2POLBLMNAPARP1EGLN1 | |
| SCHEMBL6137875 | 0.76 | MKNK1 (0.39) | NR4A2POLBLMNANOTUMSMN1; SMN2 | |
| SCHEMBL11022639 | 0.76 | ALPL (0.41) | NR4A2ALOX5POLBLMNAGAA | |
| SCHEMBL22533838 | 0.73 | PARP1 (0.42) | NR4A2PARP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499630-A1 | BCL-XL INHIBITORS | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023185986-A1 | BCL-XL INHIBITORS | BEIGENE , LTD. (KY) | 2023-10-05 | — | — | WO | disclosed |
| EP-1515956-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM (US) | 2005-08-10 | — | — | EP | disclosed |
| EP-1515956-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Smithkline Beecham (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003104209-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | NR4A2 2528/4885ALOX5 2330/4885POLB 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.